Introduction. This study provides a summary of the 2009 ERA-EDTA Registry Report, with a focus on the differences in the incidence and prevalence of haemodialysis (HD), peritoneal dialysis (PD) and renal transplantation between countries and over time. Methods. For this report, 56 data sets on renal replacement therapy (RRT) from national and regional registries in 30 countries in Europe and bordering the Mediterranean Sea were available. Data sets with individual patient data were received from 26 registries, whereas 19 registries contributed data in aggregated form. For both types of registries, we present incidence, prevalence and transplant rates. Survival analysis is based on individual patient records. (78 p.m.p.). For the cohort 2000-04, the adjusted 1-, 2-and 5-year survival of patients on RRT was 87.4% (95% confidence interval: 87.2-87.7), 78.5% (95% confidence interval: 78.2-78.8) and 56.3% (95% confidence interval: 55.9-56.7), respectively.
Introduction
This summary of the 2009 ERA-EDTA (European Renal Association-European Dialysis and Transplant Association) Registry Report includes data on renal replacement therapy (RRT) using 56 data sets from national and regional registries in 30 countries in Europe and bordering the Mediterranean Sea (Figure 1 ). Data sets with individual patient data for analysis were received from 26 national and regional registries in 14 countries, whereas 19 national registries from 19 countries contributed data only in aggregated form.
For both types of registries, we present incidence and prevalence data as well as transplant rates. In this article, we focus on differences in the incidence and prevalence of treatment modality, i.e. haemodialysis (HD), peritoneal dialysis (PD) and renal transplantation, between countries and over time. Survival analysis used the data from countries and regions that provided individual patient records.
More detailed data than those presented in the paper can be found in the 2009 ERA-EDTA Registry Report [1] that is also available on www.era-edta-reg.org.
The incidence of RRT for end-stage renal disease across Europe
In 2009, the overall incidence rate of RRT for end-stage renal disease (ESRD) among all registries reporting to the ERA-EDTA Registry was 125 per million population (p.m.p.). Figure 2 shows that the highest incidence rates at Day 1 were reported by Turkey (259 p.m.p.), Portugal (240 p.m.p.) and Greece (205 p.m.p.), whereas incidence rates <100 p.m. incidence rate of RRT for diabetic ESRD was highest in Turkey (88 p.m.p.), Israel (83 p.m.p.) and Spain, Canary Islands (73 p.m.p.) , while the registries of Iceland, Spain, Castille-La Mancha, Romania, the Netherlands, Ukraine, Montenegro, Russia, Estonia and Latvia reported incidence rates for ESRD due to diabetes mellitus <20 p.m.p. In addition, both the mean and median age of patients starting RRT in 2009 is presented in Figure 2 . The mean age ranged from 47.6 years in Russia to 69.5 years in Belgium (Dutchspeaking), while the overall mean age was 62.9 years. Table 1 shows the unadjusted incidence rate of RRT per million age-related population (p.m.a.r.p.) at Day 1 by age group. For the age group 0-19 years at the start of RRT, data were available for 20 registries from 13 countries. For an overview of paediatric RRT, data collected from those registries please visit www.espn-reg.org.
In Table 2 Figure 3 presents the distribution of the different treatment modalities in 2005 and the change in this distribution over the subsequent 5 years . Overall, we found a 0.5% decrease in HD and 1.4% decrease in PD utilization at Day 91, whereas the share of patients living on a functioning graft increased with 1.8% between 2005 and 2009. The increase over time in HD utilization was highest in Iceland (113%), UK, Northern Ireland (19.9%), UK, Wales (17.5%) and UK, Scotland (17.4%), while in Norway a decrease of À7.4% was observed. The largest decreases in PD utilization were found in the Netherlands (À5.0%) and the UK, Northern Ireland (À12.8%), Wales (À7.2%) and Scotland (À8.0%), whereas PD utilization increased in Sweden (14.4%). The share of patients living on a functioning graft at Day 91 after the start of RRT decreased between 2005 and 2009 with 11% in Iceland and increased with 4% in Norway and the Netherlands.
The prevalence of RRT for ESRD across Europe
The overall prevalence among all registries reporting to the ERA-EDTA Registry was 730 p.m.p. Figure 4 shows that the prevalence of RRT p.m.p. at 31 December 2009 was highest in Portugal (1507 p.m.p.), Belgium (French-speaking) (1193 p.m.p.) and Spain, Catalonia (1160 p.m.p.) . The lowest prevalence was reported by Ukraine (101 p.m.p.) and Russia (170 p.m.p.). Additionally, the mean and median age of prevalent patients on RRT at 31 December 2009 are presented in Figure 2 . The mean age ranged from 46.9 in Russia to 64.6 in Belgium (Dutch-speaking), while the overall mean age was 58.8 years. Table 4 shows the unadjusted prevalence of RRT p.m.a.r.p. on 31 December 2009, by age group and in Table 5 , we present the prevalence of RRT at 31 December per year over the period from 2005 to 2009 for countries and regions providing individual patient data, adjusted for age and gender distribution. Only those countries and regions with complete data from 2005 onwards are presented in this table.
As presented in In Italy, the prevalence of RRT is underestimated by~11%, due to an estimated 25-30% under-reporting of patients living on a functioning graft. Appendix 1 Statistical methods Table 8 Data presented include the survival of incident patients on RRT and of patients receiving a first transplant between 2000 and 2004 or between 2003 and 2007 with their 95% confidence intervals. Patients were followed until 31 December 2009. Statistical analysis of unadjusted survival was performed by the Kaplan-Meier method, while for the adjusted survival analyses, the Cox regression model was used. For the analysis of patient survival on RRT, the day at the start of RRT was taken as the starting point and the event studied was death. Censored observations were recovery of renal function, loss to follow-up and end of follow-up time. Regarding the analysis of patient survival on dialysis, the first day on dialysis was the starting point, the event was death and reasons for censoring were recovery of renal function, loss to follow-up, end of follow-up time and renal transplantation. In the Cox regression model, we adjusted for the fixed values of age (60 years), gender (60% men) and PRD (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other cause). For the analysis of patient and graft survival after transplantation, the date of the first renal transplantation was defined as the first day of follow-up. The event studied for the patient survival after transplantation was death, while for the graft survival, the events were graft failure and death. Reasons for censoring were loss to follow-up and end of follow-up time.
Renal transplants performed in 2009

Statistical methods to
In the adjusted analyses, we adjusted for the fixed values of age (45 years), gender (60% men) and PRD (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other cause). Patients for whom age, gender or PRD was missing were excluded. Figure 5 For the analyses of patient survival on dialysis, the starting point was Day 91 on dialysis. Analyses were adjusted for the fixed values of age (60 years), gender (60% men) and PRD (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other cause). For the analyses of patient survival after transplantation, the starting point was the time of the first transplant. Analyses were adjusted for the fixed values of age (45 years), gender (60% men) and PRD (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other cause).
Statistical methods to Figures 6 and 7
For the analyses presented in each figure, the starting point was Day 91 on dialysis. Analyses were adjusted for the fixed values of age (60 years) and gender (60% men). , by treatment modality, adjusted for age, gender and PRD. Analyses regarding incident dialysis patients were adjusted for the fixed values: age (60 years), gender (60% men) and PRD (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other cause). Analyses regarding first transplant recipients were adjusted for the fixed values: age (45 years), gender (60% men) and PRD (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other cause). 
